A patent has been granted for ATR-12, a genetically modified strain of S. epidermidis that produces a portion of human LEKTI protein. ATR-12 is under Phase 1b testing for treating Netherton syndrome. The location of this development is BRANFORD, Conn., as of May 6, 2026. Azitra, Inc. (NYSE...) is leading this innovative venture.